What are the commercial prospects for the treatment of macular degeneration (AMD) and diabetic retinopathy (DR)? This new report shows you potential revenues to 2021, discussing commercial opportunities and prospects. This report gives you market forecasts to 2021 for those retinal drugs. Discover potential revenues at total world, submarket, product and national levels. Through this research and analysis we aim to save you time and help in your decisions.
See how the drugs Lucentis, Visudyne, Avastin and Macugen can perform to 2021, finding potential revenues. For your needs, we discuss competition in this expanding market. This study discusses Roche, Novartis, Pfizer, Sanofi and other companies. There are many opportunities in AMD and DR for large and niche players. Discover prospects for existing competitors and potential market entrants from 2011 to 2021.
There is a strong R&D pipeline for treating retinal disorders. We cover products in development by Regeneron, Bayer, Allergan, OPKO, GSK, Merck, Eli Lilly, Takeda and others. This new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations.
In this report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from this survey. We provide 153 tables and charts and three research interviews (shown in the accompanying lists).
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts
This report gives you the following advantages:
* Find revenue predictions to 2021 for the world AMD and DR market and its components, seeing revenue growth
* See revenue forecasts to 2021 for leading products, assessing market potentials and competition
* Discover revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India
* Receive supporting data, including epidemiological trends and projections
* Assess leading companies providing retinal treatments, discovering their activities and outlooks
* Find out how the retinal drug industry can change and adapt from 2011 to 2021
* Investigate competition and opportunities influencing the industry and market
* See what will stimulate and restrain the industry and market from 2011
* Review R&D for AMD and DR, seeing potential for new products and drug types
* Investigate commercial requirements, identifying therapeutic needs and opportunities
* Analyse opportunities and challenges for established and emerging companies
* View opinions from three interviews with authorities on retinal treatments.
Click for report details:
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021
